Por favor, use este identificador para citar o enlazar este ítem:
http://conacyt.repositorioinstitucional.mx/jspui/handle/1000/2380| The role of afferent pulmonary innervation in poor prognosis of acute respiratory distress syndrome in COVID-19 patients and proposed use of resiniferatoxin (RTX) to improve patient outcomes in advanced disease state: A review | |
| Nahama Alexis. Ramachandran Roshni. Cisternas Alvaro Francisco. Ji Henry. | |
| Acceso Abierto | |
| Atribución-NoComercial-SinDerivadas | |
| 10.1016/j.medidd.2020.100033 | |
| Highlights•SARS-Cov-2 infection can lead to massive inflammatory responses in the lungs (cytokine storm).•Acute respiratory distress is the leading cause of high mortality associated with COVID-19.•Pulmonary innervation has been linked to immune response and modulation of inflammation.•Blocking afferent nerve signaling from the lungs might reduce severity and mortality associated with advanced stage COVID-19 disease.•Resiniferatoxin (RTX), a highly potent TRVP1 agonist can be used to delete signaling afferent nerves while preserving motor and other sensory functions.•The drug product is readily available as Sorrento just completed enrollment in two phase 1 trials, for control of pain associated with cancer and knee osteoarthritis. | |
| Medicine in Drug Discovery | |
| 2020 | |
| Artículo | |
| https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147194/pdf/main.pdf | |
| Inglés | |
| VIRUS RESPIRATORIOS | |
| Aparece en las colecciones: | Artículos científicos |
Cargar archivos:
| Fichero | Tamaño | Formato | |
|---|---|---|---|
| 1101572.pdf | 350.02 kB | Adobe PDF | Visualizar/Abrir |